Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology - United States
doi 10.1200/jco.2009.22.2679
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2009
Authors
Publisher
American Society of Clinical Oncology (ASCO)